Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study
CONCLUSION: Molidustat was noninferior to darbepoetin and maintained Hb levels in the prespecified target range in patients with renal anemia not undergoing dialysis and previously treated with ESA. Molidustat was well tolerated, and no new safety signal was observed.PMID:34569482 | DOI:10.1159/000518072
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Hiroyasu Yamamoto Kiyoshi Nobori Yoshimi Matsuda Yasuhiro Hayashi Takanori Hayasaki Tadao Akizawa Source Type: research
More News: Anemia | Aranesp | Chronic Kidney Disease | Dialysis | Japan Health | Study | Urology & Nephrology